Clinical trials: Hypogonadotrophic Hypogonadism
Secondary Hypogonadism
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with 12.5 mg…
- Trial name
- NCT01993225
- Testing
- Androxal 12.5 mg/25 mg, AndroGel 1.62%
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Repros Therapeutics Inc.
Delayed Puberty, Kallmann Syndrome
Kisspeptin in the Evaluation of Delayed Puberty
The goal of this study is to test whether the hormone kisspeptin has the potential to prospectively diagnose adolescents with self-resolving or permanent delayed puberty.
- Conditions
- Delayed Puberty, Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
- Trial name
- NCT01438034
- Testing
- kisspeptin 112-121, GnRH
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Hypogonadotropic Hypogonadism, Kallmann Syndrome
Sequential Therapy for Hypogonadotropic Hypogonadism
The traditional therapy for induction of spermatogenesis in male hypogonadotropic hypogonadism requires both HCG and human menopausal gonadotropin (HMG) or FSH until pregnancy occurs.
- Trial name
- NCT01403532
- Testing
- Traditional intervention for HH using HCG and FSH, Sequential intervention for HH using HCG and FSH, Sequential intervention for HH using HCG and FSH plus zinc
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Secondary Hypogonadism, Sexual Dysfunction
Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men
To evaluate the safety and efficacy of fispemifene in men with secondary hypogonadism and sexual side effects.
- Conditions
- Secondary Hypogonadism, Sexual Dysfunction, Erectile Dysfunction
- Trial name
- NCT02443090
- Testing
- fispemifene
- Where
- 16 sites in United States
- Volunteers
- 160 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Hypogonadism
Testosterone Replacement in Men With Diabetes and Obesity
The purpose of this study is to examine the effect of having testosterone deficiency in men with diabetes and with obesity. The study will also evaluate the effect of testosterone therapy.
- Trial name
- NCT01127659
- Testing
- testosterone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University at Buffalo
Kallmann Syndrome, Hypogonadotropic Hypogonadism
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.
- Conditions
- Kallmann Syndrome, Hypogonadotropic Hypogonadism, Hypothalamic Amenorrhea, Polycystic Ovarian Syndrome
- Trial name
- NCT01601171
- Where
- Switzerland
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Hypogonadotropic Hypogonadism
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
- Trial name
- NCT00328926
- Testing
- Luveris® 75 IU, Luveris® 25 IU, Recombinant human follicle stimulating hormone (r-hFSH)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- EMD Serono
Advanced Cancer, Hypogonadism
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
Primary Objective: 1. To determine the prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes. Secondary Objective: 1.
- Conditions
- Advanced Cancer, Hypogonadism, Pain
- Trial name
- NCT00529230
- Testing
- Questionnaire, Blood draws to assess gonadal function
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Hypogonadotropic Hypogonadism
Effect of Intranasal Insulin on LH Concentrations in Man
Over the last few years, studies have shown that men with type 2 diabetes sometimes develop a condition called hypogonadotrophic hypogonadism (HH). People with this condition produce little or no sex hormones.
- Trial name
- NCT02154477
- Testing
- intranasal insulin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Texas Tech University Health Sciences Center
Hypogonadotropic Hypogonadism, Reproductive Disorder
The Molecular Basis of Inherited Reproductive Disorders
The goal of this study is to learn more about the genes that control puberty and reproduction in humans.
- Conditions
- Hypogonadotropic Hypogonadism, Reproductive Disorder, Kallmann Syndrome, Delayed Puberty
- Trial name
- NCT05971836
- Where
- United States
- Volunteers
- 854 people
- Sponsor
- Stephanie B. Seminara, MD
Secondary Hypogonadism
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.
- Trial name
- NCT00706719
- Testing
- 25 mg Androxal, Testim 1%
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Repros Therapeutics Inc.
Effect of Treatment on Bone Mineral Density
Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism
To determine the effects of 12 months of treatment with Androxal on bone mineral density in men with secondary hypogonadism.
- Trial name
- NCT01619683
- Testing
- enclomiphene citrate
- Where
- 17 sites in United States
- Volunteers
- 300 people
- Sponsor
- Repros Therapeutics Inc.
Isolated Hypogonadotropic Hypogonadism, Kallmann Syndrome
Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)
This study will evaluate the efficacy and safety of long term use of hCG alone or hCG plus hMG in the treatment of male patients with isolated hypogonadotropic hypogonadism (IHH).
- Conditions
- Isolated Hypogonadotropic Hypogonadism, Kallmann Syndrome, Infertility
- Trial name
- IHH (NCT03687606)
- Testing
- Human Chorionic Gonadotropin, human menopausal gonadotropin
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Tongji Hospital
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
The purpose of this study is to examine the effects of testosterone deficiency in men with diabetes on atherogenesis, inflammation, cardiovascular Risk factors And adiposity .
- Trial name
- NCT00467987
- Testing
- androgel
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Secondary Hypogonadism
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
The purpose of ZA-301 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T<300 ng/dL) and normal sperm…
- Trial name
- NCT01532414
- Testing
- Androxal
- Where
- 23 sites in United States
- Volunteers
- 151 people
- Sponsor
- Repros Therapeutics Inc.
Hypogonadism, Primary Hypogonadism
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.
- Conditions
- Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
- Trial name
- TU (NCT00467870)
- Testing
- Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg
- Where
- United States
- Volunteers
- 531 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA).
- Trial name
- KASPR (NCT05633966)
- Testing
- Kisspeptin 112-121
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stephanie B. Seminara, MD
Hypogonadotropic Hypogonadism
A 6 Month Safety Extension Study of MBGS205
Phase IIb, multicentre, double-blind, randomised, placebo-controlled parallel-group 36-week study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism (HH)
- Trial name
- NCT02908074
- Testing
- BGS649
- Where
- 37 sites in United States
- Volunteers
- 143 people
- Sponsor
- Mereo BioPharma
Hypogonadotropic Hypogonadism
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
- Trial name
- NCT04648969
- Testing
- kisspeptin 112-121, GnRH
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stephanie B. Seminara, MD
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Hypogonadism in Young Men With Type 2 Diabetes
Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men.
- Trial name
- NCT01155518
- Testing
- testosterone, clomiphene
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- State University of New York at Buffalo